Publication: Pulmonary long-term consequences of COVID-19 infections after hospital discharge.
Loading...
Identifiers
Date
2021-02-18
Authors
Blanco, Jose-Ramon
Cobos-Ceballos, Maria-Jesus
Navarro, Francisco
Sanjoaquin, Isabel
Arnaiz de Las Revillas, Francisco
Bernal, Enrique
Buzon-Martin, Luis
Viribay, Miguel
Romero, Lourdes
Espejo-Perez, Simona
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Abstract
Coronavirus disease 2019 (COVID-19) survivors are reporting residual abnormalities after discharge from hospital. Limited information is available about this stage of recovery or the lingering effects of the virus on pulmonary function and inflammation. This study aimed to describe lung function in patients recovering from COVID-19 hospitalization and to identify biomarkers in serum and induced sputum samples from these patients. Patients admitted to Spanish hospitals with laboratory-confirmed COVID-19 infection by a real-time PCR (RT-PCR) assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were recruited for this study. Each hospital screened their lists of discharged patients at least 45 days after symptom onset. SARS-CoV-2-infected patients were divided into mild/moderate and severe disease groups according to the severity of their symptoms during hospitalization. Patients' epidemiological and medical histories, comorbidities, chronic treatments, and laboratory parameters were evaluated. Pulmonary function tests, the standardized 6-minute walk test (6MWT) and chest computed tomography (CT) were also performed. The levels of proteases, their inhibitors, and shed receptors were measured in serum and induced sputum samples. A total of 100 patients with respiratory function tests were included in this study. The median number of days after the onset of symptoms was 104 (IQR 89.25, 126.75). COVID-19 was severe in 47% of patients (47/100). CT was normal in 48% of patients (48/100). Lung function was normal forced expiratory volume in one second (FEV1) ≥80%, forced vital capacity (FVC) ≥80%, FEV1/FVC ≥0.7, and diffusing capacity for carbon monoxide (DLCO) ≥80% in 92% (92/100), 94% (94/100), 100% (100/100) and 48% (48/100) of patients, respectively. Multivariate analysis showed that a DLCO A diffusion deficit (DLCO<80%) was still present after hospital discharge and was associated with the most severe SARS-CoV-2 cases
Description
MeSH Terms
Adult
Aged
Biomarkers
COVID-19
COVID-19 nucleic acid testing
Comorbidity
Female
Follow-up studies
Humans
Lung
Male
Middle aged
Patient discharge
Prospective studies
Respiratory function tests
SARS-CoV-2
Spain
Survivors
Tomography, X-Ray computed
Aged
Biomarkers
COVID-19
COVID-19 nucleic acid testing
Comorbidity
Female
Follow-up studies
Humans
Lung
Male
Middle aged
Patient discharge
Prospective studies
Respiratory function tests
SARS-CoV-2
Spain
Survivors
Tomography, X-Ray computed
DeCS Terms
Alta del paciente
Biomarcadores
Comorbilidad
Prueba de ácido nucleico para COVID-19
Pruebas de función respiratoria
Pulmón
Sobrevivientes
Tomografía computarizada por rayos X
Biomarcadores
Comorbilidad
Prueba de ácido nucleico para COVID-19
Pruebas de función respiratoria
Pulmón
Sobrevivientes
Tomografía computarizada por rayos X
CIE Terms
Keywords
COVID-19, Intracellular adhesion molecule, Lung diffusion capacity, Osteoprotegerin, Plasminogen activator inhibitor, Tissue inhibitor of matrix metalloproteinases, Tomography
Citation
Blanco JR, Cobos-Ceballos MJ, Navarro F, Sanjoaquin I, Arnaiz de Las Revillas F, Bernal E, et al. Pulmonary long-term consequences of COVID-19 infections after hospital discharge. Clin Microbiol Infect. 2021 Jun;27(6):892-896